Towards a vaccine against rheumatic fever
Author Information
Author(s): L. GUILHERME, K. C. FAE, F. HIGA, L. CHAVES, S. E. OSHIRO, S. FRESCHI DE BARROS, C. PUSCHEL, M. A. JULIANO, A. C. TANAKA, G. SPINA, J. KALIL
Primary Institution: School of Medicine, Heart Institute (InCor), University of Sao Paulo, Sao Paulo, Brazil
Hypothesis
Can protective T and B cell epitopes be identified to develop a vaccine against rheumatic fever?
Conclusion
The study identified T and B cell epitopes that could potentially protect against Streptococcus pyogenes, paving the way for a vaccine.
Supporting Evidence
- Rheumatic fever affects over 20 million children worldwide, primarily in developing countries.
- Identified T and B cell epitopes showed an identical core of 16 amino acid residues.
- Antibodies against the B cell epitope inhibited bacterial invasion in vitro.
- Two regions of reactivity were found in the M protein sequence, recognized by a significant percentage of subjects.
Takeaway
Researchers are trying to create a vaccine to protect kids from a serious illness caused by a throat infection, and they found parts of the bacteria that might help the body fight it off.
Methodology
The study involved testing 620 human blood samples against overlapping peptides of the M protein from Streptococcus pyogenes to identify T and B cell epitopes.
Limitations
Epidemiological data from many developing countries are poor, and the actual number of RHD cases is likely higher than reported.
Participant Demographics
The study included 296 patients (129 with RF and 167 with RHD) and 324 healthy subjects.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website